BioCentury
ARTICLE | Company News

Vernalis Parkinson's disease deals

November 5, 2005 2:36 AM UTC

Vernalis (LSE:VER; VNLS) entered into two separate Parkinson's disease (PD) deals with Mylan (MYL) and Britannia (London, U.K.). VER acquired exclusive North American marketing rights to MYL's Apokyn apomorphine injection, which is marketed to treat "off" episodes associated with PD, for $23 million in cash. VER will complete certain Phase IV studies. The non-ergoline dopamine agonist has Orphan Drug status. VER said it expects 2006 revenues of $6-$7.5 million for the product, which was launched in the U.S in July 2004. ...